Keros Therapeutics Inc News - KROS | ADVFN

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

Home
Investing
Stocks
USA
NASDAQ
Keros Therapeutics Inc (KROS)
Keros Therapeutics Inc (KROS) News

Keros Therapeutics Inc (KROS)

11.84

0.45

(3.95%)

Closed January 24 4:00PM

Delayed by 15 minutes

11.51

-0.33

( -2.79% )

Pre Market: 7:33AM

Delayed by 15 minutes

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]

Form 8-K - Current report

Keros Therapeutics Announces Effectiveness of Global License Agreement with Takeda to Advance Elritercept

LEXINGTON, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”...

Form 8-K - Current report

Keros Therapeutics Announces Additional Update on the Phase 2 TROPOS Trial

LEXINGTON, Mass., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”...

Form 8-K - Current report

Form 8-K - Current report

Keros Therapeutics Announces Update on the Phase 2 TROPOS Trial

Keros will host an update call and webcast today, December 12, 2024, at 8:00 a.m. ET LEXINGTON, Mass., Dec...

Keros Therapeutics Presents Clinical Data from its Elritercept Program at the 66th American Society of Hematology Annual Meeting and Exposition

Elritercept demonstrated a durable transfusion independence in lower-risk myelodysplastic syndromes, including...

Form 8-K - Current report

Keros Therapeutics Announces Global License Agreement with Takeda to Advance Elritercept

Keros Therapeutics to receive upfront payment of $200 million and is eligible to receive development, approval...

Form 8-K - Current report

Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences

LEXINGTON, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”...

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

1
Next

TheFinalCD

TheFinalCD 2 weeks ago

$KROS halts all dosing in the TROPOS Phase 2 clinical trial of cibotercept (KER-012) based on the ongoing safety review due to new observations of pericardial effusion adverse events

https://x.com/BioStocks/status/1879492237891080688

$KROS the TROPOS trial is being terminated early. The Co continues to expect to present topline data from all treatment arms in this trial in Q2
https://x.com/BioStocks/status/1879493199288586404

retireat40

retireat40 1 month ago

Wow. What a turd

retireat40

retireat40 1 month ago

Shocked this is still sub 18

Dennis14

Dennis14 2 months ago

Bought in at 18.00

Monksdream

Monksdream 4 months ago

KROS more upside possible

Monksdream

Monksdream 11 months ago

KROS new 52=week high

Keros Therapeutics

Delayed Upgrade Clock